Release Date: July 1, 2026
Valid for Credit through: June 30, 2027
Program Overview:
This CME/CE program will provide an evidence-based review of biosimilar therapeutics for patients with relapsing multiple sclerosis, with a focus on approval standards, clinical evidence, and practical implications for neurologists as well as for the broader healthcare team. The program will distinguish between generic and biosimilar medications, emphasizing the differences in molecule complexity, regulatory pathways, required clinical evidence, and immunogenicity testing. Neuroinflammatory disease expert faculty Dr. Benjamin M. Greenberg, will review real-world concerns associated with certain generic MS therapies, as well as with the growing safety and efficacy data supporting biosimilars across the neurology, rheumatology, oncology, and gastroenterology treatment landscapes. Dr. Greenberg will examine biosimilar natalizumab, and rituximab, as well as emerging anti-CD20 biosimilar data, including clinical trial results, switching evidence, and real-world patient experiences. To conclude, the program will address patient counseling strategies, the nocebo effect, access and cost considerations for biosimilars, and the important role of shared decision-making in biosimilar adoption to improve outcomes and quality of life for patients with MS.
Target Audience
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Learning Objectives:
- Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of biosimilar therapeutics in treatment planning
- Review and analyze clinical trial data for biosimilar therapeutics to manage patients with MS
Course Faculty
Benjamin M. Greenberg, MD, MHS, FANA, FAAN, CRND
Distinguished Teaching Professor
Vice Chair for Clinical and Translational Research
Department of Neurology
Director, Perot Foundation Neurosciences Translational Research Center
O’Donnell Brain Institute
University of Texas Southwestern
Dallas, TX
Provided by:
